You are here

menopause

Astellas builds case for menopause drug fezolinetant

Astellas builds case for menopause drug fezolinetant

Pharmaphorum

Flag link:

A New Drug For Menopausal Hot Flashes, Veozah, Faces Access Challenges

A New Drug For Menopausal Hot Flashes, Veozah, Faces Access Challenges

Forbes

Flag link:

Astellas rolls out national Veozah campaign for treating menopause symptoms

Astellas rolls out national Veozah campaign for treating menopause symptoms

Medical Marketing and Media

Flag link:

Genentech starting to adopt menopause benefits as they work on recruiting and retaining female employees

Genentech starting to adopt menopause benefits as they work on recruiting and retaining female employees

Time

employee benefits

Flag link:

Astellas reports data from Phase IIIb trial to treat VMS due to menopause

Astellas reports data from Phase IIIb trial to treat VMS due to menopause

Clinical Trials Arena

clinical trials

Flag link:

Cash-strapped Acer sees menopause drug flunk phase 2 trial

Cash-strapped Acer sees menopause drug flunk phase 2 trial

Fierce Biotech

Acer Therapeutics

clinical trials

Flag link:

Astellas has menopause accelerated approval ambition thwarted by FDA at last minute

Astellas has menopause accelerated approval ambition thwarted by FDA at last minute

Fierce Biotech

Flag link:

Astellas buys Super Bowl commercial spot to raise menopause awareness

Astellas buys Super Bowl commercial spot to raise menopause awareness

Medical Marketing and Media

DTC advertising

Flag link:

What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision

What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision

Endpoints

patient education

Flag link:

Astellas reports Phase III data of fezolinetant for menopause-linked VMS

Astellas reports Phase III data of fezolinetant for menopause-linked VMS

Clinical Trials Arena

clinical trials

vasomotor symptoms

Flag link:

Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record

Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record

Fierce Biotech

clinical trials

Flag link:

Astellas' menopause drug suffers rare setback as failed Asian trial blots previously pristine record

Astellas' menopause drug suffers rare setback as failed Asian trial blots previously pristine record

Fierce Biotech

clinical trials

Flag link:

Astellas’ eyes filings for menopause drug fezolinetant after ph3 win

Astellas’ eyes filings for menopause drug fezolinetant after ph3 win

Pharmaforum

clinical trials

Flag link:

Amyris to buy women’s wellness firm MenoLabs

Amyris to buy women’s wellness firm MenoLabs

Pharmaceutical Business Review

Flag link:

FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish

FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish

Fierce Biotech

clinical trials

Flag link:

Meet 8 Female Founders Disrupting The $600 Billion Menopause Market

Meet 8 Female Founders Disrupting The $600 Billion Menopause Market

Forbes

Flag link:

Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff

Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff

Endpoints

clinical trials

Flag link:

Bayer inks $425M upfront KaNDy buyout to challenge Astellas for menopause market

Bayer inks $425M upfront KaNDy buyout to challenge Astellas for menopause market

Fierce Biotech

KaNDy Therapeutics

Flag link:

Astellas pushes non-hormonal menopause drug into phase 3

Astellas pushes non-hormonal menopause drug into phase 3

Pharmaforum

clinical trials

Flag link:

Concept Device Designed to Tame Menopausal Hot Flashes

Concept Device Designed to Tame Menopausal Hot Flashes

Medical Devices and Diagnostics Industry

Cambridge Consultants

Flag link:

Pages